These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11400666)

  • 1. [Molecular modeling in the battle against AIDS. Drugs design in the development of substrate-like HIV protease inhibitors].
    Klebe G
    Pharm Unserer Zeit; 2001; 30(3):194-201. PubMed ID: 11400666
    [No Abstract]   [Full Text] [Related]  

  • 2. Evolutionary analysis of HIV-1 protease inhibitors: Methods for design of inhibitors that evade resistance.
    Stoffler D; Sanner MF; Morris GM; Olson AJ; Goodsell DS
    Proteins; 2002 Jul; 48(1):63-74. PubMed ID: 12012338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 protease folding and the design of drugs which do not create resistance.
    Broglia R; Levy Y; Tiana G
    Curr Opin Struct Biol; 2008 Feb; 18(1):60-6. PubMed ID: 18160276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New ammunition in the battle against AIDS].
    Agosto M
    Sidahora; 1997; ():25-6. PubMed ID: 11364803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative studies on inhibitors of HIV protease: a target for drug design.
    Jayaraman S; Shah K
    In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive inhibitors of the HIV-1 protease.
    Ohtaka H; Freire E
    Prog Biophys Mol Biol; 2005 Jun; 88(2):193-208. PubMed ID: 15572155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of potent HIV-1 protease inhibitors incorporating sulfoximine functionality.
    Lu D; Vince R
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5614-9. PubMed ID: 17822899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug resistance of HIV-1 protease against JE-2147: I47V mutation investigated by molecular dynamics simulation.
    Bandyopadhyay P; Meher BR
    Chem Biol Drug Des; 2006 Feb; 67(2):155-61. PubMed ID: 16492163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands.
    Ghosh AK; Schiltz G; Perali RS; Leshchenko S; Kay S; Walters DE; Koh Y; Maeda K; Mitsuya H
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1869-73. PubMed ID: 16480871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-guided design of C2-symmetric HIV-1 protease inhibitors based on a pyrrolidine scaffold.
    Blum A; Böttcher J; Heine A; Klebe G; Diederich WE
    J Med Chem; 2008 Apr; 51(7):2078-87. PubMed ID: 18348517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis.
    Chellappan S; Kiran Kumar Reddy GS; Ali A; Nalam MN; Anjum SG; Cao H; Kairys V; Fernandes MX; Altman MD; Tidor B; Rana TM; Schiffer CA; Gilson MK
    Chem Biol Drug Des; 2007 May; 69(5):298-313. PubMed ID: 17539822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.
    Ghosh AK; Osswald HL; Prato G
    J Med Chem; 2016 Jun; 59(11):5172-208. PubMed ID: 26799988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [An important point of attach in AIDS treatment. HIV protease inhibitors: state of the art].
    Clement B
    Pharm Unserer Zeit; 2001; 30(3):208-11. PubMed ID: 11400668
    [No Abstract]   [Full Text] [Related]  

  • 14. Beta-lactam compounds as apparently uncompetitive inhibitors of HIV-1 protease.
    Sperka T; Pitlik J; Bagossi P; Tözsér J
    Bioorg Med Chem Lett; 2005 Jun; 15(12):3086-90. PubMed ID: 15893929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of HIV protease inhibitors: a survey.
    Ren S; Lien EJ
    Prog Drug Res; 2001; Spec No():1-34. PubMed ID: 11548206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization and computational evaluation of a series of potential active site inhibitors of the V82F/I84V drug-resistant mutant of HIV-1 protease: an application of the relaxed complex method of structure-based drug design.
    Perryman AL; Lin JH; Andrew McCammon J
    Chem Biol Drug Des; 2006 May; 67(5):336-45. PubMed ID: 16784458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the open-flap conformation of HIV-1 protease with pyrrolidine-based inhibitors.
    Böttcher J; Blum A; Dörr S; Heine A; Diederich WE; Klebe G
    ChemMedChem; 2008 Sep; 3(9):1337-44. PubMed ID: 18720485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
    Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezácová P; Brynda J; Pokorná J; Plesek J; Grüner B; Grantz Sasková K; Václavíková J; Král V; Konvalinka J
    J Med Chem; 2008 Aug; 51(15):4839-43. PubMed ID: 18598016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AIDS. The exorcists.
    Gorman C
    Time; 1996; 148(14):64-6. PubMed ID: 10161476
    [No Abstract]   [Full Text] [Related]  

  • 20. [HIV-protease inhibitors: pros and cons].
    Briones C; Soriano V
    Med Clin (Barc); 1999 May; 112(18):702-5. PubMed ID: 10374204
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.